GMED$95.46
Chart
Performance
Key Stats
AI GMED Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
BuyGlobus Medical demonstrates strong fundamental health and positive thematic alignment, though current technical indicators suggest a period of consolidation or slight downward pressure. It offers a balanced risk/reward profile for investors seeking exposure to the medical device sector.
Thematic
Globus Medical is positioned to benefit from trends in musculoskeletal health and surgical innovation, but faces competition and the evolving regulatory landscape in healthcare.
Fundamental
Globus Medical exhibits strong revenue growth, improving profitability, and a healthy balance sheet. Its valuation, while not cheap, is supported by its financial performance and market position.
Technical
While the stock maintains a long-term upward trend, recent performance indicates weakness. Key moving averages are trending downwards, and oscillators suggest a cautious outlook, signaling potential for further price declines or consolidation.
| Factor | Score |
|---|---|
| Musculoskeletal Health Demand | 85 |
| Surgical Technology & Robotics | 80 |
| Medical Device Innovation | 75 |
| Healthcare Regulatory Environment | 50 |
| Market Competition | 60 |
| Factor | Score |
|---|---|
| Valuation | 60 |
| Profitability | 70 |
| Growth | 85 |
| Balance Sheet Health | 90 |
| Cash Flow | 95 |
| Factor | Score |
|---|---|
| Trend Analysis | 40 |
| Momentum | 45 |
| Volume Confirmation | 60 |
| Support & Resistance | 75 |
| Short-term Oscillators | 55 |
AI Investing Checklist
Powered by LiveAIBullish Points (7)
Strong EPS Surprises
The company has consistently beaten EPS estimates in recent quarters (e.g., Q4 2024: +27.95%, Q2 2024: +26.87%), indicating effective cost management and operational efficiency.
Robust Cash Position
As of Q4 2024, the company holds $784.44 million in cash and cash equivalents, exceeding its total debt of $537.19 million, suggesting strong liquidity and low short-term financial risk.
Bearish Points (7)
Elevated P/E Ratio
The trailing P/E ratio is 39.77, and the forward P/E (based on Q1 2025 estimates) is 109.6, suggesting the stock may be trading at a premium compared to its earnings.
EPS Miss in Latest Quarter
Q2 2025 EPS estimate was $0.74, but the reported EPS was $0.68, a miss of 8.6%, signaling potential challenges in meeting future earnings expectations.
Calendar
August 2025
8
Next Earnings Date
H: $0.82
A: $0.75
L: $0.72
H: 745.30M
A: 742.73M
L: 737.30M
Profile
Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers musculoskeletal solutions, including spine products, such as traditional fusion implants, and treatment options for motion preservation technologies, and interventional solutions to treat vertebral compression fractures; orthopedic trauma solutions, which includes fracture plating, intramedullary nailing, and regenerative biologic products; hip and knee joint solutions, including modular hip stems and acetabular cups for total hip arthroplasty, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants; and neuromonitoring services, which provides onsite and remote monitoring of the neurological systems of patients undergoing spinal and brain-related surgeries. The company also offers enabling technologies, such as imaging, navigation, and robotics (INR) solutions for assisted surgery, which includes the ExcelsiusGPS platform, a robotic guidance and navigation system for minimally invasive and open procedures with screw and interbody spacer placement applications; Surgimap, a surgical planning software platform; Excelsius3D, a platform combined with ExcelsiusGPS that provides an intraoperative, image-guided robotic navigation solution; ExcelsiusHub, which provides real-time patient array monitoring, tissue sparing drills, and registration flexibility; and ExcelsiusFlex, a total knee arthroplasty robotic solution. Further, it distributes human cell, tissue, and cellular and tissue-based products. The company sells its products through direct or distributor sales representatives, as well as hip and knee products through independent sales agents. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.
Seasonals
Price Target
83.00 USD
The 39 analysts offering 1 year price forecasts for GMED have a max estimate of 105.00 and a min estimate of 65.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 90
A leading provider of transplant diagnostics, offering testing services for pre- and post-transplant monitoring, directly complementary to organ transplantation and preservation.
Weight: 85
Specializes in non-invasive prenatal testing and organ transplant rejection testing (Prospera), making it a direct peer in the transplant diagnostic space.
Weight: 85
A global leader in products and services for individuals with renal diseases, directly addressing end-stage kidney disease which often necessitates organ transplantation.
Weight: 80
A major pharmaceutical company with a significant portfolio of immunosuppressant drugs (e.g., cyclosporine, everolimus) critical for preventing organ rejection post-transplant.